Taflotan, the first preservative-free prostaglandin F2α analogue: treatment advantages in primary open-angle glaucoma patients

Abstract

Received: 15.01.201615.01. Accepted: 18.03.2016 G Over the past 15 years, the negative role of toxic preservatives in the IOP-lowering eye drops solutions used in the treatment of primary open angle glaucoma (POAG) patients has been convincingly proven by many national and foreign experts. Therefore, there is a worldwide tendency to prescribe preferably preservative-free IOP-lowering eye drops nowadays. Taflotan is the world's first preservative-free prostaglandin F2a analogue. In our study of POAG patients switched to Taflotan from the benzalkonium chloride-preserved latanoprost eye drops, we observed a marked decrease in corneal staining and severity of conjunctival hyperemia, as well as increase of the tear breakup time and corneal epithelium morphology improvement evaluated by confocal tomography. Thus, the drug not only effectively lowers IOP but also produces less negative effect on the tear film and eyeball surface, improving treatment tolerability.G